Read by QxMD icon Read

Estrogen therapy

Feng Lv, Wei-Hua Jin, Xian-Lin Zhang, Zhong-Rui Wang, Ai-Jun Sun
Tamoxifen treatment is important assistant for estrogen-receptor-positive breast cancer (BRCA) after resection. This study aimed to identify signatures for predicting the prognosis of patients with BRCA after tamoxifen treatment. Data of gene-specific DNA methylation (DM), as well as the corresponding clinical data for the patients with BRCA, were obtained from The Cancer Genome Atlas and followed by systematic bioinformatics analyses. After mapping these DM CPG sites onto genes, we finally obtained 352 relapse-free survival (RFS) associated DM genes, with which 61,776 gene pairs were combined, including 1,614 gene pairs related to RFS...
December 7, 2018: Journal of Cellular Physiology
Hua Jiang, Jingjing Fan, Lin Cheng, Pan Hu, Renbin Liu
Background: Most breast cancers are estrogen dependent and were sensitive to endocrine therapy, and genistein (GEN) shows strong affinity with human oestrogen receptor beta (ERβ). Purpose: The present study aimed to investigate the anticancer activity of GEN in breast cancer cell lines that constitutively expressing ERβ1 in vitro and in vivo. Methods: MCF-7/ERβ1 and MDA-MB-231/ERβ1 cell sub-lines were established through lentiviral infection...
2018: OncoTargets and Therapy
Ji-In Bang, Hai-Jeon Yoon, Bom Sahn Kim
BACKGROUND: The aim of this study was to investigate the metabolism of the spleen, bone marrow (BM), and liver from preoperative F-18 FDG PET/CT scans for the prediction of recurrence in breast cancer. METHODS: We retrospectively included 153 patients diagnosed with invasive ductal carcinoma (IDC) of the breast who underwent preoperative F-18 FDG PET/CT scan and a curative operation. The mean standardized uptake value (SUVmean) of the spleen, liver, and BM and maximum SUV (SUVmax) of primary tumors were measured...
2018: PloS One
Utthara Nayar, Ofir Cohen, Christian Kapstad, Michael S Cuoco, Adrienne G Waks, Seth A Wander, Corrie Painter, Samuel Freeman, Nicole S Persky, Lori Marini, Karla Helvie, Nelly Oliver, Orit Rozenblatt-Rosen, Cynthia X Ma, Aviv Regev, Eric P Winer, Nancy U Lin, Nikhil Wagle
Seventy percent of breast cancers express the estrogen receptor (ER), and agents that target the ER are the mainstay of treatment. However, virtually all people with ER+ breast cancer develop resistance to ER-directed agents in the metastatic setting. Beyond mutations in the ER itself, which occur in 25-30% of people treated with aromatase inhibitors1 -4 , knowledge about clinical resistance mechanisms remains incomplete. We identified activating HER2 mutations in metastatic biopsies from eight patients with ER+ metastatic breast cancer who had developed resistance to aromatase inhibitors, tamoxifen or fulvestrant...
December 10, 2018: Nature Genetics
Ana Elisa Ribeiro, Naice Eleidane Santana Monteiro, Anna Valéria Gueldini de Moraes, Lucia Helena Costa-Paiva, Adriana Orcesi Pedro
OBJECTIVE: To evaluate the effect of isoflavone administration, either in conjunction with probiotic use or not, on the symptoms of genitourinary syndrome of menopause, and compare the effects with those of hormone therapy. METHODS: A randomized clinical trial was conducted on 60 postmenopausal women aged 40 to 60 years, randomly assigned to receive oral isoflavone (150 mg dry extract of glycine max) alone or isoflavone plus probiotic (Lactobacillus acidophilus, Lactobacillus casei, Lactococcus lactis, Bifidobacterium bifidum, and Bifidobacterium lactis) or hormone therapy (1 mg estradiol and 0...
December 10, 2018: Menopause: the Journal of the North American Menopause Society
Takuma Harada, Ayako Ijima
Palbociclib is the world's first cyclin dependent kinase (CDK) 4 and 6 inhibitor. It's believed that palbociclib stops the cell cycle progression by inhibiting the activity of the complex consisting of CDK 4/6 and cyclin D, and suppresses tumor growth. In preclinical study using nonclinical model, it was confirmed that most of the cell lines sensitive to palbociclib are estrogen receptor (ER) positive. In addition, it was suggested that the expression of retinoblastoma protein (Rb) is needed for palbociclib to show its antitumor effect...
2018: Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
Akshayya Pawar, Priyanka Prabhu
The phenomenal rise in cancer over the past few years has made it the second leading cause of death worldwide. Breast cancer constitutes the predominant cancer encountered in women. Triple negative breast cancer (TNBC) is the most notorious form of breast cancer which involves absence of the estrogen, progesterone and human epidermal growth factor receptor (EGFR) on breast cancer cells. It is a real challenge for oncologists owing to the recurrence and metastasis which result in poor prognosis. Conventional therapies employed in treatment of TNBC suffer from issues of poor bioavailability, poor cellular uptake, resistance, and undesirable off-site toxicities...
December 3, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
Sandra Halldorsdottir, Hanna Dahlstrand, Karin Stålberg
BACKGROUND: Prolonged survival in ovarian and endometrial cancer patients increases the importance of paying attention to quality of life. Hormone replacement therapy (HRT) after gynecologic cancer has been controversial. With this survey, we sought to describe Swedish gynecologists' and gynecologic oncologists' attitudes towards prescribing HRT to these cancer survivors and see if prescribing practice is consistent with the available evidence and national guidelines. MATERIAL AND METHODS: A web-based survey containing three hypothetical cases with a total of 15 questions was distributed to gynecologists and gynecologic oncologists in Sweden...
December 10, 2018: Upsala Journal of Medical Sciences
Jonathan T Lei, Xuxu Gou, Matthew J Ellis
Estrogen receptor alpha gene ( ESR1 ) fusion transcripts have been identified in breast cancer but their role in breast cancer is not completely understood. Here, we report a causal role for ESR1 fusions in driving both endocrine therapy resistance and metastasis, and describe a therapeutic strategy to target ESR1 fusion-induced growth.
2018: Molecular & Cellular Oncology
Jesse M Mast, Periannan Kuppusamy
Triple-negative breast cancer (TNBC) refers to a group of biologically aggressive breast cancers that do not express estrogen, progesterone or epidermal growth factor receptor 2 hormone receptors. Each subset of TNBC has a unique molecular profile and may require specific treatments. A combination of surgery and chemotherapy followed by radiation therapy is the standard treatment mode for TNBC patients. Tumor oxygen status (hypoxia) is a key factor that may compromise the effectiveness of radiation treatment, as it is known that hypoxia can confer radiation resistance...
2018: Frontiers in Oncology
Hyun Yang, Seung Yeon Lee, Sang R Lee, Bo-Jeong Pyun, Hye Jin Kim, Young Ho Lee, Sun Woo Kwon, Dong Ho Suh, Choong Hwan Lee, Eui-Ju Hong, Hye Won Lee
Polycystic ovary syndrome (PCOS) is an endocrinal disorder that afflicts mainly women of childbearing age. The symptoms of PCOS are irregular menstrual cycles, weight gain, subfertility and infertility. However, because the etiology is unclear, management and treatment methods for PCOS are not well established. Recently, natural substances have been used for PCOS therapy. Ecklonia cava ( E. cava ) is a well-known natural substance that attenuates the effects of inflammation, allergies, and cancer. In this study, we investigated the effects of E...
2018: Frontiers in Pharmacology
Sadat Pusina
Introduction: Breast cancer is the most common malignant tumor in women. On the list of causes of death immediately after lung cancer. It is a heterogeneous disease, considering the differences in morphological, cytogenetic, molecular, clinical and therapeutic aspects, so that the prognosis in a patient with the same histological grade and pathological status may vary. Aim: In this paper we wanted to identify the correlation between the assay of the serum values of uPA-PAI-1 complexes and individual prognostic-predictive parameters, primarily with the status of estrogenic (Er), progesterogenic (PgR) and Her-2 receptors ("human epidermal growth factor)...
November 2018: Medical Archives
Stephen Johnston, Shannon Puhalla, Duncan Wheatley, Alistair Ring, Peter Barry, Chris Holcombe, Jean Francois Boileau, Louise Provencher, André Robidoux, Mothaffar Rimawi, Stuart A McIntosh, Ibrahim Shalaby, Robert C Stein, Michael Thirlwell, David Dolling, James Morden, Claire Snowdon, Sophie Perry, Chester Cornman, Leona M Batten, Lisa K Jeffs, Andrew Dodson, Vera Martins, Arjun Modi, C Kent Osborne, Katherine L Pogue-Geile, Maggie Chon U Cheang, Norman Wolmark, Thomas B Julian, Kate Fisher, Mairead MacKenzie, Maggie Wilcox, Cynthia Huang Bartlett, Maria Koehler, Mitch Dowsett, Judith M Bliss, Samuel A Jacobs
PURPOSE: CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of combination palbociclib plus letrozole as neoadjuvant therapy. PATIENTS AND METHODS: Postmenopausal women with ER-positive primary BC and tumors greater than or equal to 2.0 cm were randomly assigned 3:2:2:2 to letrozole (2.5 mg/d) for 14 weeks (A); letrozole for 2 weeks, then palbociclib plus letrozole to 14 weeks (B); palbociclib for 2 weeks, then palbociclib plus letrozole to 14 weeks (C); or palbociclib plus letrozole for 14 weeks...
December 6, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Karen M Wheeler, Devang Sharma, Parviz K Kavoussi, Ryan P Smith, Raymond Costabile
INTRODUCTION: Clomiphene citrate (CC) is a selective estrogen receptor modulator that has been used for the treatment of hypogonadism in men since the 1970s. It acts centrally to increase secretion of luteinizing hormone and follicle-stimulating hormone, thereby increasing testosterone production and serum levels. Unlike testosterone replacement therapy, CC does not suppress the hypothalamic-pituitary-gonadal axis, preserving intratesticular testosterone production and spermatogenesis...
December 3, 2018: Sexual Medicine Reviews
Ahmed Ibrahim, Luisa Hugerth, Linnea Hases, Ashish Saxena, Maike Seifert, Quentin Thomas, Jan-Åke Gustafsson, Lars Engstrand, Cecilia Williams
Chronic inflammation of the colon (colitis) is a risk factor for colorectal cancer (CRC). Hormone-replacement therapy reduces CRC incidences, and the estrogen receptor beta (ERβ/ESR2) has been implicated in this protection. Gut microbiota is altered in both colitis and CRC and may influence the severity of both. Here we test the hypothesis that intestinal ERβ impacts the gut microbiota. Mice with and without intestine-specific deletion of ERβ (ERβKOVil ) were generated using the Cre-LoxP system. Colitis and CRC were induced with a single intraperitoneal injection of azoxymethane (AOM) followed by administration of three cycles of dextran sulfate sodium (DSS) in drinking water...
December 4, 2018: International Journal of Cancer. Journal International du Cancer
Rosamaria Lappano, Yves Jacquot, Marcello Maggiolini
Breast cancer is the most prevalent cancer found in women living in developed countries. Endocrine therapy is the mainstay of treatment for hormone-responsive breast tumors (about 70% of all breast cancers) and implies the use of selective estrogen receptor modulators and aromatase inhibitors. In contrast, triple-negative breast cancer (TNBC), a highly heterogeneous disease that may account for up to 24% of all newly diagnosed cases, is hormone-independent and characterized by a poor prognosis. As drug resistance is common in all breast cancer subtypes despite the different treatment modalities, novel therapies targeting signaling transduction pathways involved in the processes of breast carcinogenesis, tumor promotion and metastasis have been subject to accurate consideration...
December 2, 2018: International Journal of Molecular Sciences
Tala Al-Rousan, Jeffrey A Sparks, Mary Pettinger, Rowan Chlebowski, JoAnn E Manson, Andrew M Kauntiz, Robert Wallace
IMPORTANCE: Carpal tunnel syndrome (CTS) is a common and debilitating condition that commonly affects postmenopausal women. OBJECTIVE: To determine the effect of menopausal hormone therapy (HT) in healthy postmenopausal women on CTS risk. DESIGN: We conducted a secondary analysis of the Women's Health Initiative's (WHI) HT trials linked to Medicare claims data. Separate intention-to-treat analyses were performed for the two trials; the conjugated equine estrogens alone (CEE alone) and the trial of CEE plus medroxyprogesterone acetate (MPA) trial...
2018: PloS One
David J Finitsis, Brittany A Vose, Justin G Mahalak, Andrew L Salner
OBJECTIVE: Adjuvant Endocrine Therapy (AET) significantly reduces risk of breast cancer recurrence in those patients whose tumor tests hormone (estrogen and/or progesterone) receptor positive. Many who are prescribed AET do not adhere adequately. Studies have sought to examine the effects of interventions to enhance patients' AET adherence, with strikingly mixed results. In order to reconcile a disparate literature, this paper aims to (1) quantitatively review the aggregate effect of interventions designed to optimize AET adherence within the current literature; and (2)meta-analyze these effects across studies' by intervention design...
December 4, 2018: Psycho-oncology
Kuanrong Li, Garnet Anderson, Vivian Viallon, Patrick Arveux, Marina Kvaskoff, Agnès Fournier, Vittorio Krogh, Rosario Tumino, Maria-Jose Sánchez, Eva Ardanaz, María-Dolores Chirlaque, Antonio Agudo, David C Muller, Todd Smith, Ioanna Tzoulaki, Timothy J Key, Bas Bueno-de-Mesquita, Antonia Trichopoulou, Christina Bamia, Philippos Orfanos, Rudolf Kaaks, Anika Hüsing, Renée T Fortner, Anne Zeleniuch-Jacquotte, Malin Sund, Christina C Dahm, Kim Overvad, Dagfinn Aune, Elisabete Weiderpass, Isabelle Romieu, Elio Riboli, Marc J Gunter, Laure Dossus, Ross Prentice, Pietro Ferrari
BACKGROUND: Few published breast cancer (BC) risk prediction models consider the heterogeneity of predictor variables between estrogen-receptor positive (ER+) and negative (ER-) tumors. Using data from two large cohorts, we examined whether modeling this heterogeneity could improve prediction. METHODS: We built two models, for ER+ (ModelER+ ) and ER- tumors (ModelER- ), respectively, in 281,330 women (51% postmenopausal at recruitment) from the European Prospective Investigation into Cancer and Nutrition cohort...
December 3, 2018: Breast Cancer Research: BCR
Krystyna Serkies, Anna Abacjew-Chmyłko, Magdalena Wieczorek-Rutkowska, Rafał Pęksa
OBJECTIVES: Endocrine therapy is the recommended systemic treatment for steroid receptor positive endometrial stromal sarcoma (ESS). There is no current consensus on the optimal hormonal therapy for ESS. The literature offers several reports on advanced/recurrent/metastatic ESS patients treated with progestins, whereas data on the efficacy of aromatase inhibitors are scarce. MATERIAL AND METHODS: We retrospectively identified cases treated for ESS with aromatase inhibitors at our institutions...
2018: Ginekologia Polska
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"